Articles related to SKIN CANCER
Eruptive Seborrheic Keratosis: A Perilous Clue
This case of a 51-year-old man with a 1-month history of multiple eruptive seborrheic keratoses on his back and a single painless nodule on his chest exemplifies the importance of performing a thorough evaluation in patients presenting with sudden-onset eruptive seborrheic keratoses.
Dermatology July 6th 2022
Something Fishy About Tuna and Melanoma Risk
Examining data on nearly half a million participants from the NIH-AARP Diet and Health Study revealed that individuals in the highest quintile of total fish intake had a 22% higher risk for malignant melanoma compared to those in the bottom quintile.
Dermatology July 5th 2022
Does Aspirin Reduce the Risk of Invasive Melanoma in Older Adults?
A randomized trial showed no significant difference in the rate of invasive melanoma between patients taking daily aspirin and those taking a placebo. There were slightly fewer melanoma events in the aspirin group than in the placebo group — 177 and 189, respectively — but the difference between the groups was not statistically significant (hazard ratio [HR], 0.94; 95% CI, 0.77-1.16; P =.58). Similarly, there were slightly fewer invasive melanoma events in the aspirin group than in the placebo group — 76 and 94, respectively — but the between-group difference was not significant (HR, 0.81; 95% CI, 0.60-1.10; P =.18).
Oncology, Medical March 22nd 2022
Neoadjuvant Therapy for Melanoma: New and Evolving Concepts
Interest in immune-modulating neoadjuvant therapy for melanoma is growing. It is possible that BRAF/MEK inhibition will be more effective in the neoadjuvant than in the adjuvant setting because of the effect of the tumor biomass. And the benefits neoadjuvant therapy would offer in assessing biologic response assessment to treatment are significant. In this review the authors discuss the rationale for this treatment approach, summarize completed and ongoing neoadjuvant clinical trials, and contextualize these findings within the growing body of knowledge about targeted and immune checkpoint therapy.
Dermatology February 8th 2022
Results of KEYNOTE-716 Trial May ‘Level the Playing Field Against Melanoma’
The results, presented during the virtual ESMO Congress 2021, will substantially change the population of patients with melanoma who undergo treatment in the adjuvant setting, according to Jason J. Luke, MD: “Patients with stage IIB/C melanoma have similar rates of recurrence and melanoma specific survival to those with stage IIIA/B disease. Despite this, adjuvant anti-PD-1 immunotherapy has only been available in standard practice for stage III disease. The results of KEYNOTE-716 will facilitate access to anti-PD-1 for stage IIB/C patients and, in a sense, level the playing field against melanoma.”
Dermatology December 21st 2021